Cheaper asthma drug on the horizon? new biosimilar QL2302 enters human testing
NCT ID NCT07327697
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 trial will compare a single dose of QL2302, a proposed biosimilar of the asthma drug Tezspire, against the original drug in 178 healthy adults aged 18 to 45. The study is double-blinded and randomized, meaning neither participants nor researchers know who gets which treatment. The main goal is to see if the two drugs behave similarly in the body and have comparable safety and immune responses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QL2302 (a proposed biosimilar of tezepelumab)
What this could lead to
If successful, this could support the development of a more affordable version of Tezspire for treating severe asthma.
What could go wrong
This is an early Phase 1 study in healthy people, not patients. It only tests a single dose, so it cannot show whether the drug works for any disease. Side effects or immune reactions may still occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••